214 related articles for article (PubMed ID: 10024010)
1. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
[TBL] [Abstract][Full Text] [Related]
2. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
[TBL] [Abstract][Full Text] [Related]
3. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
4. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
[TBL] [Abstract][Full Text] [Related]
5. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
6. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
[TBL] [Abstract][Full Text] [Related]
8. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
[TBL] [Abstract][Full Text] [Related]
9. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
Barc S; Page G; Barrier L; Garreau L; Guilloteau D; Fauconneau B; Chalon S
J Neurochem; 2002 Feb; 80(3):365-74. PubMed ID: 11905985
[TBL] [Abstract][Full Text] [Related]
10. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls.
Eisensehr I; Linke R; Tatsch K; Kharraz B; Gildehaus JF; Wetter CT; Trenkwalder C; Schwarz J; Noachtar S
Sleep; 2003 Aug; 26(5):507-12. PubMed ID: 12938802
[TBL] [Abstract][Full Text] [Related]
11. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
12. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
13. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.
Pinborg LH; Videbaek C; Svarer C; Yndgaard S; Paulson OB; Knudsen GM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):623-31. PubMed ID: 11976800
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu M; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
Eur J Nucl Med; 1998 May; 25(5):531-4. PubMed ID: 9575250
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
[TBL] [Abstract][Full Text] [Related]
16. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
[TBL] [Abstract][Full Text] [Related]
18. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S
J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
[TBL] [Abstract][Full Text] [Related]
20. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
